We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib , as well as the selective type II inhibitor DDR1-IN-1 .
O O O O O O O B-GeneOrGeneProduct I-GeneOrGeneProduct I-GeneOrGeneProduct O O O B-DiseaseOrPhenotypicFeature O B-ChemicalEntity O B-ChemicalEntity O O O O O O O O O B-ChemicalEntity O